147 related articles for article (PubMed ID: 18929897)
21. Synergistic copathogens--HIV-1 and HSV-2.
Corey L
N Engl J Med; 2007 Feb; 356(8):854-6. PubMed ID: 17314346
[No Abstract] [Full Text] [Related]
22. Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Acyclovir to prevent HIV infection?
Hicks CB
AIDS Clin Care; 2007 Oct; 19(10):84-5. PubMed ID: 18398997
[No Abstract] [Full Text] [Related]
23. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
24. An addition to the effect of treating co-infections on HIV-1 viral load.
Modjarrad K; Vermund SH
Lancet Infect Dis; 2011 Feb; 11(2):81. PubMed ID: 21272789
[No Abstract] [Full Text] [Related]
25. HSV-2 suppression reduces HIV and HSV shedding.
Collins S
GMHC Treat Issues; 2005 Dec; 19(12):11. PubMed ID: 16909510
[No Abstract] [Full Text] [Related]
26. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.
Lingappa JR; Baeten JM; Wald A; Hughes JP; Thomas KK; Mujugira A; Mugo N; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Magaret AS; Wang RS; Kidoguchi L; Barnes L; Ridzon R; Corey L; Celum C;
Lancet; 2010 Mar; 375(9717):824-33. PubMed ID: 20153888
[TBL] [Abstract][Full Text] [Related]
27. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection.
Celum CL; Robinson NJ; Cohen MS
J Infect Dis; 2005 Feb; 191 Suppl 1():S107-14. PubMed ID: 15627220
[TBL] [Abstract][Full Text] [Related]
28. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial.
Paz-Bailey G; Sternberg M; Puren AJ; Markowitz LE; Ballard R; Delany S; Hawkes S; Nwanyanwu O; Ryan C; Lewis DA
J Infect Dis; 2009 Oct; 200(7):1039-49. PubMed ID: 19715417
[TBL] [Abstract][Full Text] [Related]
29. Developments in STD/HIV interactions: the intertwining epidemics of HIV and HSV-2.
Reynolds SJ; Quinn TC
Infect Dis Clin North Am; 2005 Jun; 19(2):415-25. PubMed ID: 15963880
[TBL] [Abstract][Full Text] [Related]
30. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania.
Watson-Jones D; Weiss HA; Rusizoka M; Changalucha J; Baisley K; Mugeye K; Tanton C; Ross D; Everett D; Clayton T; Balira R; Knight L; Hambleton I; Le Goff J; Belec L; Hayes R; ;
N Engl J Med; 2008 Apr; 358(15):1560-71. PubMed ID: 18337596
[TBL] [Abstract][Full Text] [Related]
31. Utility of episodic acyclovir therapy for HSV-2 in Africa.
Sena AC; Leone P
Sex Transm Dis; 2012 Jan; 39(1):25-7. PubMed ID: 22183841
[No Abstract] [Full Text] [Related]
32. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
[TBL] [Abstract][Full Text] [Related]
33. Hypertrophic perianal herpes successfully treated with imiquimod.
Lestre SI; João A; Carvalho C; Serrão VV
An Bras Dermatol; 2011; 86(6):1185-8. PubMed ID: 22281910
[TBL] [Abstract][Full Text] [Related]
34. HSV-2 and HIV: consequences of an endemic opportunistic infection.
Wald A; Schacker T; Corey L
STEP Perspect; 1997; 9(3):2-4. PubMed ID: 11364936
[TBL] [Abstract][Full Text] [Related]
35. Atypical presentations of genital herpes simplex virus in HIV-1 and HIV-2 effectively treated by imiquimod.
McKendry A; Narayana S; Browne R
Int J STD AIDS; 2015 May; 26(6):441-3. PubMed ID: 24912536
[TBL] [Abstract][Full Text] [Related]
36. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
Kim HN; Wang J; Hughes J; Coombs R; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Fuchs J; Eshleman SH; Khaki L; McMahon MA; Siliciano RF; Wald A; Celum C
J Infect Dis; 2010 Sep; 202(5):734-8. PubMed ID: 20649426
[TBL] [Abstract][Full Text] [Related]
37. Decreased monocyte activation with daily acyclovir use in HIV-1/HSV-2 coinfected women.
Redd AD; Newell K; Patel EU; Nalugoda F; Ssebbowa P; Kalibbala S; Frank MA; Tobian AA; Gray RH; Quinn TC; Serwadda D; Reynolds SJ
Sex Transm Infect; 2015 Nov; 91(7):485-8. PubMed ID: 25904747
[TBL] [Abstract][Full Text] [Related]
38. No protective effect of acyclovir on HIV disease progression in a cohort of HSV-2-HIV-infected individuals.
Suligoi B; Dorrucci M; Volpi A; Andreoni M; Rezza G;
Antivir Ther; 2002 Dec; 7(4):289-91. PubMed ID: 12553484
[TBL] [Abstract][Full Text] [Related]
39. Aciclovir for dual infection with HIV and HSV.
Verjans GM; Boucher CA
Lancet Infect Dis; 2012 Jun; 12(6):424-5. PubMed ID: 22433278
[No Abstract] [Full Text] [Related]
40. Role of HSV-2 suppressive therapy for HIV prevention.
Reynolds SJ
Future Microbiol; 2009 Nov; 4(9):1095-7. PubMed ID: 19895212
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
